Legislation under consideration in the Tennessee General Assembly would prohibit efforts to increase the transparency of the federal program, which requires drug manufacturers to sell discounted drugs to specific entities with the goal of expanding affordable healthcare but does not require hospitals to transfer these savings directly to the prices consumers pay for drugs.
The legislative summary for Senate Bill (SB) 1414, by State Senator Richard Briggs (R-Knoxville), claims the legislation would expand an existing law that prohibits “discrimination against 340B entities. ” 340 B entities are specific hospitals and clinics that receive lower prices for prescription drugs under the federal 340B Drug Pricing Program established under the Public Health Service Act of 1992.
Read the full story
